The DOI matches its Crossref record.
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma
Abstract
Background: Preclinical models show sequence‐dependent synergy with the combination of temozolomide and irinotecan, and a Phase I trial has demonstrated the combination to be tolerable and active in children with relapsed solid tumors. Because responses were seen in patients with Ewing sarcoma (ES) on that trial, additional patients were treated with this combination following study completion. Procedure: We reviewed data from all ES patients treated with temozolomide and irinotecan at four institutions, including seven patients treated on the above Phase I trial. Results: Sixteen patients received a total of 95 courses, with a median of five courses per patient. All patients had either progressive disease (PD) during initial therapy (n = 5) or relapse within 2 years of diagnosis (n = 11). Twelve patients had metastatic disease at diagnosis, including 5 with bone and/or marrow metastases. Patients received oral temozolomide 100 mg/m 2/day on days 1–5 plus intravenous irinotecan 10–20 mg/m 2/day on days 1–5 and 8–12, with courses repeated every 21–28 days. We observed 1 complete, 3 partial, and 3 minor responses in 14 evaluable patients, with a median duration of response of 30 weeks. Planned 21‐day courses were tolerable and no more toxic than 28‐day courses. Myelosuppression was minimal despite heavy pretreatment. Grade 3–4 diarrhea occurred in 11% of courses and was related to higher irinotecan doses. Over 600 irinotecan doses were administered uneventfully at home. Conclusions: Temozolomide and protracted intravenous irinotecan given in 21‐day courses was tolerable and active in patients with advanced ES. Home administration of irinotecan with temozolomide was safe and is reasonable palliative therapy. A formal Phase II study using a uniform dose and schedule is warranted to better define activity. Pediatr Blood Cancer 2007;48:132–139. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 37
- 10.1056/NEJMoa020890 · DOI · Paper page
- 10.1200/JCO.2003.10.033 · DOI · Paper page
- 10.1200/JCO.2000.18.17.3108 · DOI · Paper page
- 10.1002/mpo.10240 · DOI · Paper page
- 10.1093/annonc/mdg457 · doi:10.1093/annonc/mdg457
- 10.1002/mpo.10248 · DOI
- 10.1016/S1040-8428(01)00154-8 · DOI
- Frohlich B, 1999, High‐dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS, Klin Padiatr, 211, 284
- 10.1016/1040-8428(96)00201-6 · doi:10.1016/1040-8428(96)00201-6
- Houghton PJ, 2000, Antitumor activity of temozolomide combined with irinotecan is partly independent of O6‐methylguanine‐DNA methyltransferase and mismatch repair phenotypes in xenograft models, Clin Cancer Res, 6, 4110
- 10.1007/BF00686188 · DOI · Paper page
- 10.1038/bjc.1996.398 · DOI
- 10.1200/JCO.1999.17.6.1815 · DOI · Paper page
- Patel VJ, 2000, Schedule‐dependent activity of temozolomide plus CPT‐11 against a human central nervous system tumor‐derived xenograft, Clin Cancer Res, 6, 4154
- Donafrancesco A, 2003, Temozolomide in resistant or relapsed pediatric solid tumors: A phase II study, Proc Am Soc Clin Oncol, 810a
- Pourquier P, 2001, Topoisomerase I‐mediated cytotoxicity of N‐methyl‐N′‐nitro‐N‐nitrosoguanidine: Trapping of topoisomerase I by the O6‐methylguanine, Cancer Res, 61, 53
- Stupp R, 2003, Temozolomide and irinotecan for primary brain tumors: A dose escalation study, Proc Am Soc Clin Oncol, 104a
- Badruddoja M, Phase 1 study of temozolomide plus irinotean (CPT‐11) in adults with recurrent malignant glioma, Proc Am Soc Clin Oncol, 2003, 102a
- 10.1097/01.coc.0000045852.88461.80 · DOI
- Jones SF, 2003, Phase I. Trial of irinotecan and temozolomide in patients with solid tumors, Oncology (Huntingt), 17, 41
- 10.1158/1078-0432.CCR-03-0175 · DOI
- 10.1016/S0031-3955(05)70541-1 · DOI · Paper page
- 10.1259/bjr.73.875.11144795 · doi:10.1259/bjr.73.875.11144795
- 10.1016/0360-3016(95)00031-S · doi:10.1016/0360-3016(95)00031-s
- 10.1093/jnci/93.18.1401 · DOI
- 10.1148/radiol.2252011604 · doi:10.1148/radiol.2252011604
- 10.1093/jnci/92.3.205 · DOI · Paper page
- Furman W, 2003, . Cefixime enables further dose escalation or oral irinotecan in pediatric patients with refractory solid tumors, Proc Am Soc Clin Oncol, 799a
- Thompson J, 1997, Efficacy of systemic administration of irinotecan against neuroblastoma xenografts, Clin Cancer Res, 3, 423
- Takasuna K, 1996, Involvement of beta‐glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT‐11) in rats, Cancer Res, 56, 3752
- 10.1200/JCO.2003.08.175 · DOI
- 10.1038/bjc.1998.555 · DOI
- Blaney S, 2001, A phase I study of irinotecan in pediatric patients: A pediatric oncology group study, Clin Cancer Res, 7, 32
- 10.1097/00043426-200202000-00007 · DOI
- 10.1097/00043426-200202000-00009 · doi:10.1097/00043426-200202000-00009
- 10.1002/pbc.20107 · doi:10.1002/pbc.20107
- 10.1200/JCO.2001.19.15.3463 · DOI · Paper page
Cited by
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Malempati, S., & Hawkins, D. S. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24118 · Cited by 422
NCCN Guidelines Insights: Bone Cancer, Version 2.2017
Biermann, J. S., Chow, W., Reed, D. R., Lucas, D., Adkins, D. R., Agulnik, M., Benjamin, R. S., Brigman, B., Budd, G. T., Curry, W. T., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0017 · Cited by 294
Murphey, M. D., Senchak, L. T., Mambalam, P. K., Logie, C. I., Klassen-Fischer, M. K., & Kransdorf, M. J. (2013) · RadioGraphics · doi:10.1148/rg.333135005 · Cited by 293
Metadata
- Authors
- Wagner, L. M., McAllister, N., Goldsby, R. E., Rausen, A. R., McNall‐Knapp, R. Y., McCarville, M. B., & Albritton, K.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2005-11-29
- Volume
- 48
- Issue
- 2
- Pages
- 132-139
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2129148702
- Cited by
- 197
- References
- 0
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. https://app.cochat.ai/papers/10.1002/pbc.20697
- The paper
- Wagner, L. M., McAllister, N., Goldsby, R. E., Rausen, A. R., McNall‐Knapp, R. Y., McCarville, M. B., & Albritton, K. (2007). Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.20697
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.